http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 22 Oct 2026 16:05:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/AbCellera+to+Present+at+Upcoming+Investor+Conferences+in+November+2026/27222542.html <p> VANCOUVER, British Columbia--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.abcellera.com&amp;esheet=54626978&amp;newsitemid=20261022914583&amp;lan=en-US&amp;anchor=AbCellera&amp;index=1&amp;md5=460ea32b381c46ee5a92dba6375cfdd3" shape="rect">AbCellera</a> (Nasdaq: ABCL) announced that<b> </b>the Company will present at the following investor conferences: </p><ul class="bwlistdisc"> <li> Stifel Healthcare Conference, November 11, 2026 </li> <li> Jefferies Global Healthcare Conference in London, November 16, 2026 </li> </ul><p> A live audio webcast of the presentation may be accessed through a link that will be posted on <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Finvestors.abcellera.com%2Foverview%2Fdefault.aspx&amp;esheet=54626978&amp;newsitemid=20261022914583&amp;lan=en-US&amp;anchor=AbCellera%27s+Investor+Relations+website&amp;index=2&amp;md5=b21092a215378a7a141fa5c0c0c08d61" shape="rect">AbCellera's Investor Relations website</a>. A replay will be available through the same link following the presentation. </p><p> <b>About AbCellera Biologics Inc.</b> </p><p> <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.abcellera.com&amp;esheet=54626978&amp;newsitemid=20261022914583&amp;lan=en-US&amp;anchor=AbCellera&amp;index=3&amp;md5=ac1a48b9e46cd109a0e9dfa403191eaf" shape="rect">AbCellera</a> (Nasdaq: ABCL) is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody-based medicines in the http://www.streetinsider.com/Press+Releases/AbCellera+to+Present+at+Upcoming+Investor+Conferences+in+November+2026/27222542.html Thu, 22 Oct 2026 16:05:00 -0400 ABCL http://www.streetinsider.com/Business+Wire/AbCellera+to+Present+at+Upcoming+Investor+Conferences+in+November+2026/27222542.html <p> VANCOUVER, British Columbia--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.abcellera.com&amp;esheet=54626978&amp;newsitemid=20261022914583&amp;lan=en-US&amp;anchor=AbCellera&amp;index=1&amp;md5=460ea32b381c46ee5a92dba6375cfdd3" shape="rect">AbCellera</a> (Nasdaq: ABCL) announced that<b> </b>the Company will present at the following investor conferences: </p><ul class="bwlistdisc"> <li> Stifel Healthcare Conference, November 11, 2026 </li> <li> Jefferies Global Healthcare Conference in London, November 16, 2026 </li> </ul><p> A live audio webcast of the presentation may be accessed through a link that will be posted on <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Finvestors.abcellera.com%2Foverview%2Fdefault.aspx&amp;esheet=54626978&amp;newsitemid=20261022914583&amp;lan=en-US&amp;anchor=AbCellera%27s+Investor+Relations+website&amp;index=2&amp;md5=b21092a215378a7a141fa5c0c0c08d61" shape="rect">AbCellera's Investor Relations website</a>. A replay will be available through the same link following the presentation. </p><p> <b>About AbCellera Biologics Inc.</b> </p><p> <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.abcellera.com&amp;esheet=54626978&amp;newsitemid=20261022914583&amp;lan=en-US&amp;anchor=AbCellera&amp;index=3&amp;md5=ac1a48b9e46cd109a0e9dfa403191eaf" shape="rect">AbCellera</a> (Nasdaq: ABCL) is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody-based medicines in the http://www.streetinsider.com/Business+Wire/AbCellera+to+Present+at+Upcoming+Investor+Conferences+in+November+2026/27222542.html Thu, 22 Oct 2026 16:05:00 -0400 ABCL http://www.streetinsider.com/Press+Releases/AI+Can+Design+Antibodies+Faster+Than+Anyone+Can+Check+Them+for+Immune+Risk.+That+Gap+Is+Starting+to+Close./27214511.html <p><strong>News Provided by Wall Street Investor on behalf of MindWalk Holdings Corp.</strong></p><p align="left">AUSTIN, Texas, Oct. 21, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=PHsesr3ir6dvYJJmrAHhWUh_0Nrhr1V9ArQHDLXeFPR1fApRSnV2vCz7qS_IRAZf_LNN0G5n90_NHe67JVk0og==" rel="nofollow" target="_blank"><em>Wall Street Investor</em></a><em> News Commentary</em> - Antibodies have become one of medicine’s most valuable drug classes, with 144 FDA-approved antibody drugs on the market as of August 2025 and global sales of more than $267 billion in 2024, according to a review published in the Journal of Biomedical Science. Artificial intelligence is now generating antibody candidates by the thousands. The harder question is whether the patient’s immune system will accept them, and checking that early, http://www.streetinsider.com/Press+Releases/AI+Can+Design+Antibodies+Faster+Than+Anyone+Can+Check+Them+for+Immune+Risk.+That+Gap+Is+Starting+to+Close./27214511.html Wed, 21 Oct 2026 10:00:00 -0400 ABCL ABSI AMD HYFT NVDA http://www.streetinsider.com/Globe+Newswire/AI+Can+Design+Antibodies+Faster+Than+Anyone+Can+Check+Them+for+Immune+Risk.+That+Gap+Is+Starting+to+Close./27214511.html <p><strong>News Provided by Wall Street Investor on behalf of MindWalk Holdings Corp.</strong></p><p align="left">AUSTIN, Texas, Oct. 21, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=PHsesr3ir6dvYJJmrAHhWUh_0Nrhr1V9ArQHDLXeFPR1fApRSnV2vCz7qS_IRAZf_LNN0G5n90_NHe67JVk0og==" rel="nofollow" target="_blank"><em>Wall Street Investor</em></a><em> News Commentary</em> - Antibodies have become one of medicine’s most valuable drug classes, with 144 FDA-approved antibody drugs on the market as of August 2025 and global sales of more than $267 billion in 2024, according to a review published in the Journal of Biomedical Science. Artificial intelligence is now generating antibody candidates by the thousands. The harder question is whether the patient’s immune system will accept them, and checking that early, http://www.streetinsider.com/Globe+Newswire/AI+Can+Design+Antibodies+Faster+Than+Anyone+Can+Check+Them+for+Immune+Risk.+That+Gap+Is+Starting+to+Close./27214511.html Wed, 21 Oct 2026 10:00:00 -0400 ABCL ABSI AMD HYFT NVDA http://www.streetinsider.com/Press+Releases/AI+Can+Design+Antibodies+Faster+Than+Anyone+Can+Check+Them+for+Immune+Risk.+That+Gap+Is+Starting+to+Close./27214511.html <p><strong>News Provided by Wall Street Investor on behalf of MindWalk Holdings Corp.</strong></p><p align="left">AUSTIN, Texas, Oct. 21, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=PHsesr3ir6dvYJJmrAHhWUh_0Nrhr1V9ArQHDLXeFPR1fApRSnV2vCz7qS_IRAZf_LNN0G5n90_NHe67JVk0og==" rel="nofollow" target="_blank"><em>Wall Street Investor</em></a><em> News Commentary</em> - Antibodies have become one of medicine’s most valuable drug classes, with 144 FDA-approved antibody drugs on the market as of August 2025 and global sales of more than $267 billion in 2024, according to a review published in the Journal of Biomedical Science. Artificial intelligence is now generating antibody candidates by the thousands. The harder question is whether the patient’s immune system will accept them, and checking that early, http://www.streetinsider.com/Press+Releases/AI+Can+Design+Antibodies+Faster+Than+Anyone+Can+Check+Them+for+Immune+Risk.+That+Gap+Is+Starting+to+Close./27214511.html Wed, 21 Oct 2026 10:00:00 -0400 ABCL ABSI AMD HYFT NVDA http://www.streetinsider.com/Globe+Newswire/AI+Can+Design+Antibodies+Faster+Than+Anyone+Can+Check+Them+for+Immune+Risk.+That+Gap+Is+Starting+to+Close./27214511.html <p><strong>News Provided by Wall Street Investor on behalf of MindWalk Holdings Corp.</strong></p><p align="left">AUSTIN, Texas, Oct. 21, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=PHsesr3ir6dvYJJmrAHhWUh_0Nrhr1V9ArQHDLXeFPR1fApRSnV2vCz7qS_IRAZf_LNN0G5n90_NHe67JVk0og==" rel="nofollow" target="_blank"><em>Wall Street Investor</em></a><em> News Commentary</em> - Antibodies have become one of medicine’s most valuable drug classes, with 144 FDA-approved antibody drugs on the market as of August 2025 and global sales of more than $267 billion in 2024, according to a review published in the Journal of Biomedical Science. Artificial intelligence is now generating antibody candidates by the thousands. The harder question is whether the patient’s immune system will accept them, and checking that early, http://www.streetinsider.com/Globe+Newswire/AI+Can+Design+Antibodies+Faster+Than+Anyone+Can+Check+Them+for+Immune+Risk.+That+Gap+Is+Starting+to+Close./27214511.html Wed, 21 Oct 2026 10:00:00 -0400 ABCL ABSI AMD HYFT NVDA http://www.streetinsider.com/Press+Releases/AI+Can+Design+Antibodies+Faster+Than+Anyone+Can+Check+Them+for+Immune+Risk.+That+Gap+Is+Starting+to+Close./27214511.html <p><strong>News Provided by Wall Street Investor on behalf of MindWalk Holdings Corp.</strong></p><p align="left">AUSTIN, Texas, Oct. 21, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=PHsesr3ir6dvYJJmrAHhWUh_0Nrhr1V9ArQHDLXeFPR1fApRSnV2vCz7qS_IRAZf_LNN0G5n90_NHe67JVk0og==" rel="nofollow" target="_blank"><em>Wall Street Investor</em></a><em> News Commentary</em> - Antibodies have become one of medicine’s most valuable drug classes, with 144 FDA-approved antibody drugs on the market as of August 2025 and global sales of more than $267 billion in 2024, according to a review published in the Journal of Biomedical Science. Artificial intelligence is now generating antibody candidates by the thousands. The harder question is whether the patient’s immune system will accept them, and checking that early, http://www.streetinsider.com/Press+Releases/AI+Can+Design+Antibodies+Faster+Than+Anyone+Can+Check+Them+for+Immune+Risk.+That+Gap+Is+Starting+to+Close./27214511.html Wed, 21 Oct 2026 10:00:00 -0400 ABCL ABSI AMD HYFT NVDA http://www.streetinsider.com/Globe+Newswire/AI+Can+Design+Antibodies+Faster+Than+Anyone+Can+Check+Them+for+Immune+Risk.+That+Gap+Is+Starting+to+Close./27214511.html <p><strong>News Provided by Wall Street Investor on behalf of MindWalk Holdings Corp.</strong></p><p align="left">AUSTIN, Texas, Oct. 21, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=PHsesr3ir6dvYJJmrAHhWUh_0Nrhr1V9ArQHDLXeFPR1fApRSnV2vCz7qS_IRAZf_LNN0G5n90_NHe67JVk0og==" rel="nofollow" target="_blank"><em>Wall Street Investor</em></a><em> News Commentary</em> - Antibodies have become one of medicine’s most valuable drug classes, with 144 FDA-approved antibody drugs on the market as of August 2025 and global sales of more than $267 billion in 2024, according to a review published in the Journal of Biomedical Science. Artificial intelligence is now generating antibody candidates by the thousands. The harder question is whether the patient’s immune system will accept them, and checking that early, http://www.streetinsider.com/Globe+Newswire/AI+Can+Design+Antibodies+Faster+Than+Anyone+Can+Check+Them+for+Immune+Risk.+That+Gap+Is+Starting+to+Close./27214511.html Wed, 21 Oct 2026 10:00:00 -0400 ABCL ABSI AMD HYFT NVDA http://www.streetinsider.com/Press+Releases/AI+Can+Design+Antibodies+Faster+Than+Anyone+Can+Check+Them+for+Immune+Risk.+That+Gap+Is+Starting+to+Close./27214511.html <p><strong>News Provided by Wall Street Investor on behalf of MindWalk Holdings Corp.</strong></p><p align="left">AUSTIN, Texas, Oct. 21, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=PHsesr3ir6dvYJJmrAHhWUh_0Nrhr1V9ArQHDLXeFPR1fApRSnV2vCz7qS_IRAZf_LNN0G5n90_NHe67JVk0og==" rel="nofollow" target="_blank"><em>Wall Street Investor</em></a><em> News Commentary</em> - Antibodies have become one of medicine’s most valuable drug classes, with 144 FDA-approved antibody drugs on the market as of August 2025 and global sales of more than $267 billion in 2024, according to a review published in the Journal of Biomedical Science. Artificial intelligence is now generating antibody candidates by the thousands. The harder question is whether the patient’s immune system will accept them, and checking that early, http://www.streetinsider.com/Press+Releases/AI+Can+Design+Antibodies+Faster+Than+Anyone+Can+Check+Them+for+Immune+Risk.+That+Gap+Is+Starting+to+Close./27214511.html Wed, 21 Oct 2026 10:00:00 -0400 ABCL ABSI AMD HYFT NVDA http://www.streetinsider.com/Globe+Newswire/AI+Can+Design+Antibodies+Faster+Than+Anyone+Can+Check+Them+for+Immune+Risk.+That+Gap+Is+Starting+to+Close./27214511.html <p><strong>News Provided by Wall Street Investor on behalf of MindWalk Holdings Corp.</strong></p><p align="left">AUSTIN, Texas, Oct. 21, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=PHsesr3ir6dvYJJmrAHhWUh_0Nrhr1V9ArQHDLXeFPR1fApRSnV2vCz7qS_IRAZf_LNN0G5n90_NHe67JVk0og==" rel="nofollow" target="_blank"><em>Wall Street Investor</em></a><em> News Commentary</em> - Antibodies have become one of medicine’s most valuable drug classes, with 144 FDA-approved antibody drugs on the market as of August 2025 and global sales of more than $267 billion in 2024, according to a review published in the Journal of Biomedical Science. Artificial intelligence is now generating antibody candidates by the thousands. The harder question is whether the patient’s immune system will accept them, and checking that early, http://www.streetinsider.com/Globe+Newswire/AI+Can+Design+Antibodies+Faster+Than+Anyone+Can+Check+Them+for+Immune+Risk.+That+Gap+Is+Starting+to+Close./27214511.html Wed, 21 Oct 2026 10:00:00 -0400 ABCL ABSI AMD HYFT NVDA http://www.streetinsider.com/Press+Releases/AI+Can+Design+Antibodies+Faster+Than+Anyone+Can+Check+Them+for+Immune+Risk.+That+Gap+Is+Starting+to+Close./27214511.html <p><strong>News Provided by Wall Street Investor on behalf of MindWalk Holdings Corp.</strong></p><p align="left">AUSTIN, Texas, Oct. 21, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=PHsesr3ir6dvYJJmrAHhWUh_0Nrhr1V9ArQHDLXeFPR1fApRSnV2vCz7qS_IRAZf_LNN0G5n90_NHe67JVk0og==" rel="nofollow" target="_blank"><em>Wall Street Investor</em></a><em> News Commentary</em> - Antibodies have become one of medicine’s most valuable drug classes, with 144 FDA-approved antibody drugs on the market as of August 2025 and global sales of more than $267 billion in 2024, according to a review published in the Journal of Biomedical Science. Artificial intelligence is now generating antibody candidates by the thousands. The harder question is whether the patient’s immune system will accept them, and checking that early, http://www.streetinsider.com/Press+Releases/AI+Can+Design+Antibodies+Faster+Than+Anyone+Can+Check+Them+for+Immune+Risk.+That+Gap+Is+Starting+to+Close./27214511.html Wed, 21 Oct 2026 10:00:00 -0400 ABCL ABSI AMD HYFT NVDA http://www.streetinsider.com/Globe+Newswire/AI+Can+Design+Antibodies+Faster+Than+Anyone+Can+Check+Them+for+Immune+Risk.+That+Gap+Is+Starting+to+Close./27214511.html <p><strong>News Provided by Wall Street Investor on behalf of MindWalk Holdings Corp.</strong></p><p align="left">AUSTIN, Texas, Oct. 21, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=PHsesr3ir6dvYJJmrAHhWUh_0Nrhr1V9ArQHDLXeFPR1fApRSnV2vCz7qS_IRAZf_LNN0G5n90_NHe67JVk0og==" rel="nofollow" target="_blank"><em>Wall Street Investor</em></a><em> News Commentary</em> - Antibodies have become one of medicine’s most valuable drug classes, with 144 FDA-approved antibody drugs on the market as of August 2025 and global sales of more than $267 billion in 2024, according to a review published in the Journal of Biomedical Science. Artificial intelligence is now generating antibody candidates by the thousands. The harder question is whether the patient’s immune system will accept them, and checking that early, http://www.streetinsider.com/Globe+Newswire/AI+Can+Design+Antibodies+Faster+Than+Anyone+Can+Check+Them+for+Immune+Risk.+That+Gap+Is+Starting+to+Close./27214511.html Wed, 21 Oct 2026 10:00:00 -0400 ABCL ABSI AMD HYFT NVDA http://www.streetinsider.com/New+Coverage/UBS+Starts+AbCellera+Biologics+%28ABCL%29+at+Buy/27173101.html <p>UBS analyst Alice Nettleton initiates coverage on AbCellera Biologics (NASDAQ: ABCL) with a Buy rating and a price target of $18.00.</p><p>The analyst comments: “We initiate coverage of AbCellera (ABCL) with a Buy rating and $18 PT. We see ABCL635 as a potentially transformative therapy in menopausal hot flashes, with a ~$13B commercial opportunity in menopause by 2035. Our $3.3B menopause risk-adjusted 2035 sales estimate, versus cons. at $1.5B, reflects our view that '635 can capture greater share of a larger market than investors currently anticipate. Assuming the Phase 2 efficacy and safety profile holds up in larger studies, we believe http://www.streetinsider.com/New+Coverage/UBS+Starts+AbCellera+Biologics+%28ABCL%29+at+Buy/27173101.html Mon, 12 Oct 2026 02:19:37 -0400 ABCL http://www.streetinsider.com/Analyst+Comments/UBS+Starts+AbCellera+Biologics+%28ABCL%29+at+Buy/27173101.html <p>UBS analyst Alice Nettleton initiates coverage on AbCellera Biologics (NASDAQ: ABCL) with a Buy rating and a price target of $18.00.</p><p>The analyst comments: “We initiate coverage of AbCellera (ABCL) with a Buy rating and $18 PT. We see ABCL635 as a potentially transformative therapy in menopausal hot flashes, with a ~$13B commercial opportunity in menopause by 2035. Our $3.3B menopause risk-adjusted 2035 sales estimate, versus cons. at $1.5B, reflects our view that '635 can capture greater share of a larger market than investors currently anticipate. Assuming the Phase 2 efficacy and safety profile holds up in larger studies, we believe http://www.streetinsider.com/Analyst+Comments/UBS+Starts+AbCellera+Biologics+%28ABCL%29+at+Buy/27173101.html Mon, 12 Oct 2026 02:19:37 -0400 ABCL http://www.streetinsider.com/FDA/AbCellera+to+present+Phase+12+data+on+ABCL635+at+menopause+meeting/27167009.html <p>AbCellera Biologics (Nasdaq: ABCL) announced it will present Phase 1/2 clinical data for its investigational drug ABCL635 at The Menopause Society's 2026 Annual Meeting, scheduled for October 20 to 24 at the Hilton Bayfront in San Diego, California.</p> <p>The poster presentation, titled "Safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of ABCL635, an NK3R monoclonal antibody antagonist for the treatment of vasomotor symptoms: a Phase 1/2 study," is set for October 22 from 6:15 p.m. to 7:15 p.m. PDT in the Indigo Exhibit Hall.</p> <p>AbCellera said the presentation will include new safety data from the Phase 1 multiple ascending dose study, along with new http://www.streetinsider.com/FDA/AbCellera+to+present+Phase+12+data+on+ABCL635+at+menopause+meeting/27167009.html Thu, 08 Oct 2026 16:05:25 -0400 ABCL http://www.streetinsider.com/Press+Releases/AbCellera+Announces+Presentation+of+Phase+12+Data+for+ABCL635+at+TMS+2026+Annual+Meeting/27166988.html <p> VANCOUVER, British Columbia--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.abcellera.com&amp;esheet=54617316&amp;newsitemid=20261008273252&amp;lan=en-US&amp;anchor=AbCellera&amp;index=1&amp;md5=be266cae7f9d4d994c32c70a3f9a44c1" shape="rect">AbCellera</a> (Nasdaq: ABCL) today announced an upcoming poster presentation of Phase 1/2 data on ABCL635 at The Menopause Society’s (TMS) 2026 Annual Meeting, to be held October 20 to 24 at the Hilton Bayfront in San Diego, California. </p><p> <b><i>Details on AbCellera’s poster presentation at TMS are as follows:</i></b> </p><p> <b>Title:</b> Safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of ABCL635, an NK3R monoclonal antibody antagonist for the treatment of vasomotor symptoms: a Phase 1/2 study <br /><b>Poster ID: </b>P-92 <br /><b>Date and Time:</b> Thursday, October 22 from 6:15 p.m. to 7:15 p.m. PDT <br /><b>Location:</b> Indigo Exhibit http://www.streetinsider.com/Press+Releases/AbCellera+Announces+Presentation+of+Phase+12+Data+for+ABCL635+at+TMS+2026+Annual+Meeting/27166988.html Thu, 08 Oct 2026 16:05:00 -0400 ABCL http://www.streetinsider.com/Business+Wire/AbCellera+Announces+Presentation+of+Phase+12+Data+for+ABCL635+at+TMS+2026+Annual+Meeting/27166988.html <p> VANCOUVER, British Columbia--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.abcellera.com&amp;esheet=54617316&amp;newsitemid=20261008273252&amp;lan=en-US&amp;anchor=AbCellera&amp;index=1&amp;md5=be266cae7f9d4d994c32c70a3f9a44c1" shape="rect">AbCellera</a> (Nasdaq: ABCL) today announced an upcoming poster presentation of Phase 1/2 data on ABCL635 at The Menopause Society’s (TMS) 2026 Annual Meeting, to be held October 20 to 24 at the Hilton Bayfront in San Diego, California. </p><p> <b><i>Details on AbCellera’s poster presentation at TMS are as follows:</i></b> </p><p> <b>Title:</b> Safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of ABCL635, an NK3R monoclonal antibody antagonist for the treatment of vasomotor symptoms: a Phase 1/2 study <br /><b>Poster ID: </b>P-92 <br /><b>Date and Time:</b> Thursday, October 22 from 6:15 p.m. to 7:15 p.m. PDT <br /><b>Location:</b> Indigo Exhibit http://www.streetinsider.com/Business+Wire/AbCellera+Announces+Presentation+of+Phase+12+Data+for+ABCL635+at+TMS+2026+Annual+Meeting/27166988.html Thu, 08 Oct 2026 16:05:00 -0400 ABCL http://www.streetinsider.com/Press+Releases/AbCellera+to+Report+Third+Quarter+2026+Financial+Results+on+November+9%2C+2026/27135856.html <p> VANCOUVER, British Columbia--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.abcellera.com&amp;esheet=54611167&amp;newsitemid=20260930581206&amp;lan=en-US&amp;anchor=AbCellera&amp;index=1&amp;md5=b96053fd15b1797d82421cb3c06f4184" shape="rect">AbCellera</a> (Nasdaq: ABCL) will announce its third quarter 2026 financial results on Monday, November 9, 2026, and hold an earnings conference call at 3:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day. </p><p> A live audio webcast of the earnings conference may be accessed through a link that will be posted on <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Finvestors.abcellera.com%2Foverview%2Fdefault.aspx&amp;esheet=54611167&amp;newsitemid=20260930581206&amp;lan=en-US&amp;anchor=AbCellera%26%238217%3Bs+Investor+Relations+website&amp;index=2&amp;md5=fc599dfca595638a1d55e4a1c6e689eb" shape="rect">AbCellera’s Investor Relations website</a>. A replay will be available through the same link following the conference call. </p><p> <b>About AbCellera Biologics Inc.</b> </p><p> <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.abcellera.com&amp;esheet=54611167&amp;newsitemid=20260930581206&amp;lan=en-US&amp;anchor=AbCellera&amp;index=3&amp;md5=9c3ba841052fe89b018617bcc90ce210" shape="rect">AbCellera</a> (Nasdaq: ABCL) is a clinical-stage biotechnology company focused on http://www.streetinsider.com/Press+Releases/AbCellera+to+Report+Third+Quarter+2026+Financial+Results+on+November+9%2C+2026/27135856.html Thu, 01 Oct 2026 16:05:00 -0400 ABCL http://www.streetinsider.com/Business+Wire/AbCellera+to+Report+Third+Quarter+2026+Financial+Results+on+November+9%2C+2026/27135856.html <p> VANCOUVER, British Columbia--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.abcellera.com&amp;esheet=54611167&amp;newsitemid=20260930581206&amp;lan=en-US&amp;anchor=AbCellera&amp;index=1&amp;md5=b96053fd15b1797d82421cb3c06f4184" shape="rect">AbCellera</a> (Nasdaq: ABCL) will announce its third quarter 2026 financial results on Monday, November 9, 2026, and hold an earnings conference call at 3:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day. </p><p> A live audio webcast of the earnings conference may be accessed through a link that will be posted on <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Finvestors.abcellera.com%2Foverview%2Fdefault.aspx&amp;esheet=54611167&amp;newsitemid=20260930581206&amp;lan=en-US&amp;anchor=AbCellera%26%238217%3Bs+Investor+Relations+website&amp;index=2&amp;md5=fc599dfca595638a1d55e4a1c6e689eb" shape="rect">AbCellera’s Investor Relations website</a>. A replay will be available through the same link following the conference call. </p><p> <b>About AbCellera Biologics Inc.</b> </p><p> <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.abcellera.com&amp;esheet=54611167&amp;newsitemid=20260930581206&amp;lan=en-US&amp;anchor=AbCellera&amp;index=3&amp;md5=9c3ba841052fe89b018617bcc90ce210" shape="rect">AbCellera</a> (Nasdaq: ABCL) is a clinical-stage biotechnology company focused on http://www.streetinsider.com/Business+Wire/AbCellera+to+Report+Third+Quarter+2026+Financial+Results+on+November+9%2C+2026/27135856.html Thu, 01 Oct 2026 16:05:00 -0400 ABCL http://www.streetinsider.com/New+Coverage/JPMorgan+Starts+AbCellera+Biologics+%28ABCL%29+at+Overweight%2C+%27feedback+bodes+well+overall%27/27116428.html (Updated - September 29, 2026 10:02 AM EDT) <p>JPMorgan initiates coverage on AbCellera Biologics (NASDAQ: ABCL) with a Overweight rating and a price target of $17.00.</p><p>The analyst comments "We conducted a physician pulse check in September to better understand the perception of ABCL’s lead asset, ABCL635, in menopausal hot flashes (VMS). We recruited 13 physicians who together treat a total of ~4.1K menopausal VMS patients, and asked for their qualitative and quantitative feedback on the early Week 4 data that ABCL reported in early August (see our initiation). The perception of the early VMS results was highly favorable, signaling broad appreciation http://www.streetinsider.com/New+Coverage/JPMorgan+Starts+AbCellera+Biologics+%28ABCL%29+at+Overweight%2C+%27feedback+bodes+well+overall%27/27116428.html Tue, 29 Sep 2026 10:02:31 -0400 ABCL http://www.streetinsider.com/Analyst+Comments/JPMorgan+Starts+AbCellera+Biologics+%28ABCL%29+at+Overweight%2C+%27feedback+bodes+well+overall%27/27116428.html (Updated - September 29, 2026 10:02 AM EDT) <p>JPMorgan initiates coverage on AbCellera Biologics (NASDAQ: ABCL) with a Overweight rating and a price target of $17.00.</p><p>The analyst comments "We conducted a physician pulse check in September to better understand the perception of ABCL’s lead asset, ABCL635, in menopausal hot flashes (VMS). We recruited 13 physicians who together treat a total of ~4.1K menopausal VMS patients, and asked for their qualitative and quantitative feedback on the early Week 4 data that ABCL reported in early August (see our initiation). The perception of the early VMS results was highly favorable, signaling broad appreciation http://www.streetinsider.com/Analyst+Comments/JPMorgan+Starts+AbCellera+Biologics+%28ABCL%29+at+Overweight%2C+%27feedback+bodes+well+overall%27/27116428.html Tue, 29 Sep 2026 10:02:31 -0400 ABCL http://www.streetinsider.com/Hot+Comments/JPMorgan+Starts+AbCellera+Biologics+%28ABCL%29+at+Overweight%2C+%27feedback+bodes+well+overall%27/27116428.html (Updated - September 29, 2026 10:02 AM EDT) <p>JPMorgan initiates coverage on AbCellera Biologics (NASDAQ: ABCL) with a Overweight rating and a price target of $17.00.</p><p>The analyst comments "We conducted a physician pulse check in September to better understand the perception of ABCL’s lead asset, ABCL635, in menopausal hot flashes (VMS). We recruited 13 physicians who together treat a total of ~4.1K menopausal VMS patients, and asked for their qualitative and quantitative feedback on the early Week 4 data that ABCL reported in early August (see our initiation). The perception of the early VMS results was highly favorable, signaling broad appreciation http://www.streetinsider.com/Hot+Comments/JPMorgan+Starts+AbCellera+Biologics+%28ABCL%29+at+Overweight%2C+%27feedback+bodes+well+overall%27/27116428.html Tue, 29 Sep 2026 10:02:31 -0400 ABCL http://www.streetinsider.com/Hot+New+Coverage/JPMorgan+Starts+AbCellera+Biologics+%28ABCL%29+at+Overweight%2C+%27feedback+bodes+well+overall%27/27116428.html (Updated - September 29, 2026 10:02 AM EDT) <p>JPMorgan initiates coverage on AbCellera Biologics (NASDAQ: ABCL) with a Overweight rating and a price target of $17.00.</p><p>The analyst comments "We conducted a physician pulse check in September to better understand the perception of ABCL’s lead asset, ABCL635, in menopausal hot flashes (VMS). We recruited 13 physicians who together treat a total of ~4.1K menopausal VMS patients, and asked for their qualitative and quantitative feedback on the early Week 4 data that ABCL reported in early August (see our initiation). The perception of the early VMS results was highly favorable, signaling broad appreciation http://www.streetinsider.com/Hot+New+Coverage/JPMorgan+Starts+AbCellera+Biologics+%28ABCL%29+at+Overweight%2C+%27feedback+bodes+well+overall%27/27116428.html Tue, 29 Sep 2026 10:02:31 -0400 ABCL http://www.streetinsider.com/New+Coverage/Goldman+Sachs+Resumes+AbCellera+Biologics+%28ABCL%29+at+Neutral/27098095.html (Updated - September 24, 2026 5:32 AM EDT) <p>Goldman Sachs analyst Andrea Newkirk resumes coverage on AbCellera Biologics (NASDAQ: ABCL) with a Neutral rating and a price target of $13.00.</p><p>The analyst comments "ABCL is a clinical-stage biotechnology company that leverages a proprietary, vertically integrated engine of high-throughput technologies, data science, and machine learning to discover and develop antibodies. While historically focused on partner-initiated programs to generate downstream economics per future milestone and royalty streams (thus mitigating binary risk associated with any one program), the company has more recently prioritized development of its internal pipeline, including clinical-stage candidates ABCL635 for menopausal vasomotor http://www.streetinsider.com/New+Coverage/Goldman+Sachs+Resumes+AbCellera+Biologics+%28ABCL%29+at+Neutral/27098095.html Thu, 24 Sep 2026 05:32:32 -0400 ABCL http://www.streetinsider.com/Analyst+Comments/Goldman+Sachs+Resumes+AbCellera+Biologics+%28ABCL%29+at+Neutral/27098095.html (Updated - September 24, 2026 5:32 AM EDT) <p>Goldman Sachs analyst Andrea Newkirk resumes coverage on AbCellera Biologics (NASDAQ: ABCL) with a Neutral rating and a price target of $13.00.</p><p>The analyst comments "ABCL is a clinical-stage biotechnology company that leverages a proprietary, vertically integrated engine of high-throughput technologies, data science, and machine learning to discover and develop antibodies. While historically focused on partner-initiated programs to generate downstream economics per future milestone and royalty streams (thus mitigating binary risk associated with any one program), the company has more recently prioritized development of its internal pipeline, including clinical-stage candidates ABCL635 for menopausal vasomotor http://www.streetinsider.com/Analyst+Comments/Goldman+Sachs+Resumes+AbCellera+Biologics+%28ABCL%29+at+Neutral/27098095.html Thu, 24 Sep 2026 05:32:32 -0400 ABCL